Clinical trial
An Investigation of the Effect of the Promoter Polymorphism in the…
NCT00131612 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00131612 |
|---|---|
| Title | An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 in Patients on Breast Cancer Treatment |
| Official title | An Investigation of the Effect of the Promoter Polymorphism in the Glucuronosyltransferase 2B7 Using Epirubicin Clearance and the Ratios of Epirubicin and Epirubicinol Glucuronide to Epirubicin |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | FEC 100 |
| Enrollment | 120 |
| Start date | Jan 1, 2002 |
| Primary completion | Dec 1, 2005 |
| Completion | Jan 1, 2013 |
| First posted | Aug 19, 2005 |
| Last update posted | Feb 26, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: